- Home
- Automated
- NDF A-Z listing
- Methotrexate
M
Methotrexate
Subsidy Information and Financing Scheme
SDL
SDL
SDL
MSHL
MSHL
Drug Guidance
No
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Methotrexate
General information
Subsidy Information and Financing Scheme
[SDL] Methotrexate Injection 50 mg/2 mL, 1 g/10 mL
[SDL] Methotrexate Injection (Preservative-free) 50 mg/2 mL
[SDL] Methotrexate Tablet 2.5 mg
[MSHL] Methotrexate Injection 50 mg/2 mL, 1 g/10 mL
For cancer treatment.
[MSHL] Methotrexate Tablet 2.5 mg
For cancer treatment.
Legend
This section shows the following:
Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs
Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List
Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List
As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.
Legend list
Indicator | Legend |
|---|---|
SDL | Standard Drug List |
MAF | Medical Assistance Fund |
SVL | Subsidised Vaccine List |
MSHL | Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List |
Drug Guidance for Subsidy
Not Applicable
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Injection 50 mg/2 mL |
|
Injection 1 g/10 mL |
|
Tablet 2.5 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* The following products do not have any clinical information available